![Charles Wu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charles Wu
Directeur Technique/Scientifique/R&D chez Beijing Continent Pharmaceutical Co., Ltd.
Fortune : - $ au 31/05/2024
Postes actifs de Charles Wu
Sociétés | Poste | Début | Fin |
---|---|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Directeur Technique/Scientifique/R&D | 01/01/2020 | - |
Historique de carrière de Charles Wu
Anciens postes connus de Charles Wu
Sociétés | Poste | Début | Fin |
---|
Formation de Charles Wu
University of Science & Technology of China | Undergraduate Degree |
University of Maryland | Doctorate Degree |
Tulane University (Louisiana) | Masters Business Admin |
Statistiques
Internationale
Chine | 3 |
Etats-Unis | 3 |
Opérationnelle
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Bourse
- Insiders
- Charles Wu
- Expérience